CHLOROTHIAZIDE SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Chlorothiazide Sodium, and when can generic versions of Chlorothiazide Sodium launch?
Chlorothiazide Sodium is a drug marketed by Am Regent, Fresenius Kabi Usa, Rk Pharma, Sagent Pharms Inc, and Sun Pharm. and is included in five NDAs.
The generic ingredient in CHLOROTHIAZIDE SODIUM is chlorothiazide sodium. There are forty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the chlorothiazide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chlorothiazide Sodium
A generic version of CHLOROTHIAZIDE SODIUM was approved as chlorothiazide sodium by FRESENIUS KABI USA on October 16th, 2009.
Summary for CHLOROTHIAZIDE SODIUM
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 9 |
Clinical Trials: | 4 |
Patent Applications: | 15 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in CHLOROTHIAZIDE SODIUM? | CHLOROTHIAZIDE SODIUM excipients list |
DailyMed Link: | CHLOROTHIAZIDE SODIUM at DailyMed |
Recent Clinical Trials for CHLOROTHIAZIDE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University | Phase 4 |
National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
Yale University | Phase 1 |
Pharmacology for CHLOROTHIAZIDE SODIUM
Drug Class | Thiazide Diuretic |
Physiological Effect | Increased Diuresis |